BMRN vs LUCD · P/E 40, rev $1.76B vs rev $2.7M
Biomarin Pharmaceutical Inc (BMRN) versus Lucid Diagnostics Inc (LUCD) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Lucid Diagnostics Inc (LUCD) is a medical devices company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported LUCD revenue for 2026-06-30 was $2.7M. Net income was -$25.6M. LUCD currently screens at market cap $123.3M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. LUCD currently screens at market cap $123.3M.
Not investment advice. Open the BMRN and LUCD stock pages for the full models.
Not investment advice.